Product InformationRegistration Status: Active
OXYCONTIN NEO CONTROLLED-RELEASE TABLET 80mg is approved to be sold in Singapore with effective from 2015-10-28. It is marketed by MUNDIPHARMA PHARMACEUTICALS PTE LTD, with the registration number of SIN14888P.
This product contains Oxycodone 80mg in the form of TABLET, FILM-COATED, EXTENDED-RELEASE. It is approved for ORAL use.
This product is manufactured by Purdue Pharmaceuticals L.P.(bulk production for tablets)(primary in UNITED STATES.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Oxycodone is a semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. An extended-release (ER) form of oxycodone (Xtampza ER) was approved for the management of daily, around-the-clock pain management in April, 2016.
For the treatment of diarrhoea, pulmonary oedema and for the relief of moderate to moderately severe pain.
Mechanism of Action
Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
- Well absorbed with an oral bioavailability of 60% to 87%
- * 2.6 L/kg
* 0.8 L/min [adults]
Symptoms of overdose include respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.
(-)-14-Hydroxydihydrocodeinone | 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one | 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one | 4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one | Dihydro-14-hydroxycodeinone | Dihydrohydroxycodeinone | Dihydroxycodeinone | Oxicodona | Oxycodone | Oxycodonum | Oxycodone |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.